Home › Puma Biotechnology Updates Timeline For Filing New Drug Application
 

Keywords :   


Puma Biotechnology Updates Timeline For Filing New Drug Application

2014-12-03 07:07:08| drugdiscoveryonline News Articles

Puma Biotechnology, Inc., a development stage biopharmaceutical company, recently provided an update on the timeline for filing its New Drug Application (NDA) for the approval of PB272 (neratinib) in the extended adjuvant treatment of HER2-positive early stage breast cancer

Tags: application updates drug filing

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.06Potential Tropical Cyclone One Graphics
17.06Potential Tropical Cyclone One Forecast Discussion Number 1
17.06Potential Tropical Cyclone One Wind Speed Probabilities Number 1
17.06Potential Tropical Cyclone One Public Advisory Number 1
17.06Summary for Potential Tropical Cyclone One (AT1/AL012024)
17.06Potential Tropical Cyclone One Forecast Advisory Number 1
17.06New Federal Government Filing Requirement Regarding Ownership of LLCs and Corporations
17.06Manufacturers Reps That Sell to International Customers June 26 Networking Event
More »